AstraZeneca Hints At Acquisitions, Merck And Novo Nordisk React To China Cuts – Emerging Market Earnings Roundup (Part 3)
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca plans to enhance capacity in emerging markets while cutting jobs and consolidating operations. Merck sees strong volume growth in China, and Novo Nordisk reports a slow quarterly sales growth in the Chinese human insulin market.